See Why Doctors Recommend Cerefolin®

In this video library, healthcare professionals share their perspectives on supporting patients with Mild Cognitive Impairment, along with real-world experiences, success stories, and practical insights to guide care.

Man in a gray polo shirt with a blue play button icon over his chest, set against a blurred indoor background.

Dr. Bradford Perkins, MD

Dr. Perkins is a California-based family medicine physician specializing in concierge care. He emphasizes individualized treatment approaches for patients with mild cognitive impairment (MCI), including the use of targeted nutritional support in those with elevated homocysteine or low folate levels.

Watch Full Video

Woman in a white coat with a stethoscope, likely a doctor, in an indoor setting.

Dr. Roxanne Carfora, MD

Dr. Carfora is a New York–based internal medicine physician. She focuses on identifying and supporting patients with mild cognitive impairment (MCI), including those who may benefit from targeted nutritional support. Dr. Carfora shares her perspective on which patients she considers for Cerefolin Brain Wellness® and how she counsels them on incorporating it into their care plan.

Watch Full Video

Cerefolin Brain Wellness supplement bottle with labeled ingredients on a white background

Cerefolin Brain Wellness® is Targeted Nutrition for MCI

A dual-action formula that works on two levels—improving brain function and slowing cognitive decline. Cerefolin Brain Wellness® supports memory, focus, and overall brain health. It also delivers essential nutrients that help reduce elevated homocysteine levels, a factor linked to changes in memory, focus, and long-term brain health. This product is intended to be used under the supervision of a healthcare provider.

Learn More

Reasons to Choose

Slows Brain Shrinkage
In a clinical study, patients with high homocysteine levels taking Cerefolin Brain Wellness®* showed an 11.2 times slower rate of brain atrophy compared to those not taking it.¹

Long-Term Results
Cerefolin Brain Wellness®* is backed by an MRI study and up to 7 years of clinical data from the same patients, showing long-term use may help slow cognitive decline and maintain essential brain function.^{1, 3}

Formula Includes

Active Folate – Supports the production of brain chemicals (neurotransmitters) involved in memory and focus. Also helps regulate homocysteine, a factor associated with cognitive decline and brain atrophy.

Vitamin B12 (as Methylcobalamin) - Helps maintain nerve health, support brain energy, and recycle homocysteine for long-term brain support.

N-acetylcysteine (NAC) – A powerful antioxidant that helps protect brain cells from oxidative stress.

Disclaimers

Cerefolin Brain Wellness® is a medical food for the clinical dietary management of mild cognitive impairment with hyperhomocysteinemia and is specially formulated to meet the distinctive nutritional requirements for this condition. Use under medical supervision.

**Based on prescriptions written by neurologists as a proxy for recommendation. In a 2025 survey conducted by Zappi, 93% of consumers surveyed indicated a doctor prescribing a product is a recommendation.

§ Images don’t portray actual consumers and are for illustration purposes only.

|| Testimonials based on experience with CerefolinNAC®*.

* Cerefolin Brain Wellness®, formerly known and studied as CerefolinNAC®, is the same trusted and effective product that is now free from major allergens (milk, eggs, fish, shellfish, tree nuts, peanuts, wheat, sesame and soy), dyes, and colorants.

† By submitting this information, I hereby give Alfasigma USA, Inc. authorization to release, reproduce, use or distribute information about me, in original or modified form, for promotional and educational purposes in all forms of media, including print, broadcast or Internet. This information may include my medical information if I choose to submit any. I understand my information may be shared with a third party working on Alfasigma USA, Inc.’s behalf for promotional or educational purposes. I also understand that I may be contacted by this third party or Alfasigma USA, Inc. for more information.

^†† This product should be taken under medical supervision, and you should consult your healthcare provider before taking this for mild cognitive impairment.

References

Shankle WR, et al. J Alzheimers Dis. 2016;54(3):1073-1084.
Shankle WR, et al. J Aging Res Clin Pract. 2013;2.
Hara J, et al. Nutr Health Aging. 2015;19.
Alfasigma USA, Inc. PLUS Program patient survey results. Data on file. 2012.
Alfasigma USA, Inc. Support data. Data on file. 2019-2024.
Chan A, Shea TB. J Nutr Health Aging. 2008;12(4):252-261.
de Jager CA, Oulhaj A, Jacoby R, Refsum H, Smith AD. Int J Geriatr Psychiatry. 2012;27(6):592-600.
Merrill E, Laughlin GA, Barrett-Connor E. Am J Epidemiol. 2005;162(7):644-653.
Reynolds EH. BMJ. 2000;320(7248):1512-1515.
de Jager CA, Refsum H, Smith AD. Neurobiol Aging. 2014;35(suppl 2):S35-S39.
Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA. Curr Opin Pharmacol. 2007;7(4):355-359.
Kelly GS. Altern Med Rev. 2000;5(6):467-471.
Antoniades C, Shirodaria C, Warrick N, et al. Circulation. 2006;114(11):1193-1201.
Calderón-Ospina CA, Nava-Mesa MO. CNS Neurosci Ther. 2020;26(1):5-18.
Sah RP, et al. Ann Geriatr Med Res. 2023;27(4):370-380.
Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R. Arch Neurol. 2003;60(1):59-64.
Smith AD, Refsum H. J Alzheimers Dis. 2016;54(4):1149-1166.
Seshadri S, Beiser A, Selhub J, et al. N Engl J Med. 2002;346(7):476-483.
Yao Y, Wang J, Wang J, et al. J Geriatr Cardiol. 2017;14(1):49-55.
Diaz-Arrastia R. Arch Neurol. 2000;57(10):1422-1428.
Keller AC, Kane MA, Heinze-Milne S, et al. J Appl Physiol. 2019;126(2):379-387.
Zhu Y, Liu J, Wang Y, et al. Climacteric. 2020;23(3):274-281.
Estrada DA, Ismail-Beigi F. Am J Hematol. 2001;67(3):221-227.
Luzzi S, D’Agostino V, Orlandi A, et al. Biomedicines. 2022;10(8):1892.
Diekman MJ, Anghelescu N, Endert E. Clin Endocrinol (Oxf). 2001;54(5):631-636.
Paknahad Z, Chitsaz A. Int J Prev Med. 2012;3(9):633-640.
DeSouza C, Keaney JF Jr. Drugs. 2002;62(12):1657-1670.
Myles PS, Leslie K, McNeil J, Forbes A, Chan MTV. Br J Anaesth. 2008;100(5):635-643.
Fallah S, Nouroozi V, Seifi M, Samadikuchaksaraei A. J Clin Lab Anal. 2012;26(5):360-365.
Lerman LO, Chade AR. Am J Physiol Heart Circ Physiol. 2022;322(4):H709-H720.
Troen AM, Shea-Budgell MA, Shukitt-Hale B, et al. Proc Natl Acad Sci U S A. 2008;105(34):12474-12479.
Hajj Mouhamed D, Ezzaher A, Neffati F, et al. Clin Chem Lab Med. 2011;49(6):987-993.
Smith AD, Smith SM, de Jager CA, et al. PLoS One. 2010;5(9):e12244.
Douaud G, Refsum H, de Jager CA, et al. Proc Natl Acad Sci U S A. 2013;110(23):9523-9528.
Xu M, Zhang Y, Liu Y, et al. Nutr Neurosci. 2023;26(6):417-430.
Sohouli MH, et al. Nutr Rev. 2023;82(6):726-737.